Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission
Stock Information for Minerva Neurosciences Inc
Loading
Please wait while we load your information from QuoteMedia.